March 27 (Reuters) - Dermata Therapeutics Inc DRMA.O:
BREAKING: DERMATA'S XYNGARI™ PHASE 3 TRIAL TOPLINE DATA MEETS ALL PRIMARY ENDPOINTS
DERMATA THERAPEUTICS INC - ANNOUNCES POSITIVE PHASE 3 RESULTS FOR XYNGARI IN ACNE TREATMENT
DERMATA THERAPEUTICS INC: XYNGARI™ ACHIEVED ITS PRIMARY ENDPOINTS
DERMATA THERAPEUTICS INC - TO INITIATE SECOND PHASE 3 TRIAL FOR XYNGARI IN H2 2025
Source text: ID:nPn5fjQdSa
Further company coverage: DRMA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.